Experience of therapy with Reduksin in group of patients with diabetes mellitus type 2
Abstract80% of patients with diabetes mellitus are overweight or obese. One of medications focused on obesity management is sibutramine (Reduksin®). This article gives a detailed account of its mechanisms of action, side effects and data of foreign drug administration clinical studies. Also results of the world's largest Russian safety monitoring of Reduksin application in group of patients with excess weight research are described.
Keywords:diabetes mellitus, obesity, overweight, Reduksin
Endocrinology: News, Opinions, Training. 2014; (1-2): 32–37.